FDA's Leadership Shuffle Leaves More Questions Than Answers The latest shakeup at the U. S. Food and Drug Administration has left many wondering about the future of regulation in America.
The departure of acting director Tracy Beth Høeg from the Center for Drug Evaluation and Research, as well as acting director Katherine Szarama from the Center for Biologics Evaluation and Research, raises concerns about stability and continuity at the agency.
The FDA's top leaders have been in flux since former commissioner Marty Makary's resignation.